Issue 26, 2022

Dual-amplified CRISPR-Cas12a bioassay for HIV-related nucleic acids

Abstract

Nucleic acid amplification strategies have successfully dominated ultrasensitive bioassays, but they sometimes bring high time-consumption, multi-step operation, increased contamination risk, and mismatch-related inaccuracy. We proposed a nucleic acid amplification-free method called the AuNPs-tagging based CRISPR-Cas12a bioassay platform. The signal amplification was realized by integrating the self-amplification effect of CRISPR-Cas12a with the enhancement effect of the large number of detectable atoms inside each gold nanoparticle. The proposed method achieved a low LOD of 1.05 amol in 40 min for HIV-related DNA.

Graphical abstract: Dual-amplified CRISPR-Cas12a bioassay for HIV-related nucleic acids

Supplementary files

Article information

Article type
Communication
Submitted
08 Feb 2022
Accepted
07 Mar 2022
First published
08 Mar 2022

Chem. Commun., 2022,58, 4247-4250

Dual-amplified CRISPR-Cas12a bioassay for HIV-related nucleic acids

J. Zhou, J. Hu, R. Liu, C. Wang and Y. Lv, Chem. Commun., 2022, 58, 4247 DOI: 10.1039/D2CC00792D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements